logo-loader
viewQ BioMed Inc.

Q BioMed files for FDA's Orphan Drug status for its pediatric autism drug

The company’s drug candidate QBM-001 aims to treat toddlers with pediatric nonverbal autism

Child playing
The New York company may launch clinical trials of QBM-001 in the first quarter of 2020

Q BioMed Inc (OTCMKTS:QBIO) announced Friday that it has applied for Orphan Drug status with the US regulator for its pediatric autism drug candidate QBM-001.

QBM-001 aims to treat toddlers with pediatric nonverbal autism who suffer from nonverbal or minimally verbal capabilities (PMVA). The company says there is no effective treatment available to treat an estimated 250,000 children born each year worldwide (20,000 in the US) with the affliction.

READ: Q BioMed to apply for Orphan Drug status with FDA, European regulators for its pediatric autism drug

Orphan Drug designation offers clinical development benefits including tax credits, accelerated evaluation of registration files and eligibility for seven years of market exclusivity in the US.

"We look forward to working with the US Food and Drug Administration on this application that will ultimately help us better serve these children and their families," said Q BioMed CEO Denis Corin in a statement. "Pediatric minimally verbal autism is a very underserved subset of autism and we are grateful to all the clinical psychologists, neurologists and doctors who have contributed to this filing and the differential diagnosis for this subset."

The company said Dr Pamela Ventola from the Child Study Center at Yale University, and a specialist in autism spectrum disorders, will be the primary contact for ongoing correspondence with the Office of Orphan Products Development at the FDA.

Seeking Orphan Drug status from EMA  

Earlier this month, Q BioMed indicated that it will not only ask the FDA, but also apply to the European Medicines Agency for Orphan designation.

The company said its application to EMA will be based on its recent breakthrough discovery of two biomarkers that identifies PMVA. The company's study examined 1,953 autistic biomarkers.

In the meantime, the New York-based company’s second phase of QBM-001’s formulation is expected to be finalized in August 2019.

At that time, Q BioMed said it will request a pre-investigational new drug meeting with the FDA and similar discussions with Europe's EMA. Based on regulatory guidance, Q BioMed anticipates filing its new drug meeting submissions, including its current clinical trial design, in December.

And clinical trials may commence as early as the first quarter of 2020, the company said.

Shares in Q BioMed traded flat at $1.51.

—(Updates with details, plans for Europe)—

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Q BioMed Inc.

Price: 1.55 USD

OTCMKTS:QBIO
Market: OTCQB
Market Cap: $32.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Q BioMed infuses first patient with its FDA-approved cancer...

Q BioMed Inc. (OTCQB:QBIO) CEO Denis Corin tells Proactive the New York-based biotech company, has dosed its first patient in a commercial setting with its FDA approved non-opioid drug Strontium89 for patients with pain from metastatic bone cancer. Corin says the company is working on making...

2 weeks, 3 days ago

2 min read